|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:administeredCycle
|
every 3 weeks
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:HER2-positive_breast_cancer
2019
HER2-low breast cancer
HER2-positive gastric cancer
|
|
gptkbp:ATCCode
|
gptkb:L01FG02
|
|
gptkbp:blackBoxWarning
|
interstitial lung disease
embryo-fetal toxicity
|
|
gptkbp:brand
|
gptkb:Enhertu
|
|
gptkbp:CASNumber
|
1825034-57-7
|
|
gptkbp:contains
|
gptkb:trastuzumab
deruxtecan
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Daiichi_Sankyo
|
|
gptkbp:drugClass
|
antineoplastic agent
monoclonal antibody conjugate
|
|
gptkbp:eliminationHalfLife
|
~6 days
|
|
gptkbp:EMAApproval
|
2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trastuzumab deruxtecan
|
|
gptkbp:indication
|
gptkb:gastric_or_gastroesophageal_junction_adenocarcinoma
metastatic breast cancer
unresectable breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:linkerType
|
cleavable peptide linker
|
|
gptkbp:mechanismOfAction
|
HER2-targeted antibody-drug conjugate
delivers cytotoxic topoisomerase I inhibitor
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:molecularWeight
|
~150 kDa
|
|
gptkbp:payload
|
topoisomerase I inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
fatigue
neutropenia
interstitial lung disease
|
|
gptkbp:target
|
gptkb:HER2_protein
|
|
gptkbp:bfsParent
|
gptkb:Enhertu
|
|
gptkbp:bfsLayer
|
7
|